Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3175
Title: Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry
Authors: Gentles, T. L.
Weintraub, R. G.
Justo, R. N.
Grigg, L. E.
Radford, D. J.
Hardikar, W.
Cheung, M.
Cain, T. M.
Rao, P.
Alexander, S. I.
Ayer, J.
Verrall, C.
Du Plessis, K.
Chapman, J.
Rice, K.
Barry, J.
Zannino, D.
Iyengar, A. J.
Wilson, T. G.
d'Udekem, Y.
Winlaw, D. S.
Cordina, R. L.
Celermajer, D. S.
Wheaton, G. R.
Bullock, A.
Issue Date: 2018
Source: 273 , 2018, p. 100-107
Pages: 100-107
Journal: International Journal of Cardiology
Abstract: Background: Hepatic and renal dysfunction have been observed in survivors of the Fontan procedure, however their incidence and associated factors remain poorly defined. Methods: A total of 152 participants from a Registry of 1528 patients underwent abdominal ultrasound, transient elastography (FibroScan), serum fibrosis score (FibroTest), in vivo Tc-99m DTPA measurement of glomerular filtration rate (mGFR), and urine albumin-creatinine ratio (ACR). Results: Mean age and time since Fontan were 19.8 ± 9.3 and 14.1 ± 7.6 years, respectively. Features suggestive of hepatic fibrosis were observed on ultrasound in 87/143 (61%) and no patient was diagnosed with hepatocellular carcinoma. FibroScan median kPa was ≥10 in 117/133 (88%), ≥15 in 75/133 (56%), and ≥20 in 41/133 (31%). Fifty-four patients (54/118, 46%) had a FibroTest score ≥0.49 (equivalent to ≥F2 fibrosis). FibroTest score correlated with FibroScan value (r = 0.24, p = 0.015) and ACR (r = 0.29, p = 0.002), and patients with ultrasound features of hepatic fibrosis had a higher FibroScan median kPa (19.5 vs 15.4, p = 0.002). Renal impairment was mild (mGFR 60–89 ml/min/1.73 m2) in 46/131 (35%) and moderate (mGFR 30–59 ml/min/1.73 m2) in 3/131 (2%). Microalbuminuria was detected in 52/139 participants (37%). By multivariable analysis, time since Fontan was associated with increased FibroScan median kPa (β = 0.89, 95% CI 0.54–1.25, p = 0.002) and decreased mGFR (β = −0.77, 95% CI −1.29–0.24, p = 0.005). Conclusions: In the second decade after Fontan hepatic and renal structure and function are abnormal in a significant number of patients: close to 60% have ultrasonographic evidence of structural hepatic abnormalities, 46% have elevated serum hepatic fibrosis scores, and 57% have either reduced glomerular filtration rate or microalbuminuria. Hepatic and renal function should be monitored for potential impacts on outcomes after Fontan completion.L20009832192018-07-31
2018-11-15
DOI: 10.1016/j.ijcard.2018.07.118
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L2000983219&from=exporthttp://dx.doi.org/10.1016/j.ijcard.2018.07.118 |
Keywords: FibroScan;elastographliver function test kit;pentetic acid;technetium 99m;abdominal radiography;adult;article;Australian and New Zealand Fontan Registry;child;controlled study;correlational study;cross-sectional study;echography;female;Fontan procedure;glomerulus filtration rate;human;in vivo study;kidney failure;kidney function;liver cell carcinoma;liver failure;liver fibrosis;liver function;major clinical study;male;microalbuminuria;mild renal impairment;moderate renal impairment;patient monitoring;priority journal;register;school child;transient elastography;treatment outcome;young adult;FibroTest
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

86
checked on Mar 13, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.